- Home
- Automated
- List of product information
- FLORINEF TABLET 0.1 MG [SIN10680P]
FLORINEF TABLET 0.1 MG [SIN10680P]
Active ingredients: FLORINEF TABLET 0.1 MG
Last updated 26 October 2025
On this page
Product Info
FLORINEF TABLET 0.1 MG
[SIN10680P]
Product information
Active Ingredient and Strength | FLUDROCORTISONE ACETATE - 0.1 MG |
Dosage Form | TABLET |
Manufacturer and Country | HAUPT PHARMA AMAREG GMBH - GERMANY |
Registration Number | SIN10680P |
Licence Holder | DCH AURIGA SINGAPORE |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | H02AA02 |
INDICATIONS AND USAGE
FLORINEF is indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome.
RECOMMENDED DOSAGE
Dosage depends on the severity of the disease and the response of the patient. The lowest possible dose should be used to control the condition being treated, and a reduction in dosage should be made (gradually) when possible.
Adrenocorticoid Insufficiency (chronic).
In Addison’s disease, the combination of FLORINEF with a glucocorticoid such as hydrocortisone or cortisone provides substitution therapy approximating normal adrenal activity.
The usual dose for adults, adolescents, and elderly patients is one tablet (0.1 mg) of FLORINEF daily – range: one tablet (0.1 mg) three times a week to two tablets (0.2 mg) daily. If treatment-associated hypertension develops, the dose should be reduced to 0.05 mg daily. FLORINEF is preferably administered in conjunction with cortisone (10 mg to 37.5 mg daily in divided doses) or hydrocortisone (10 mg to 30 mg daily in divided doses).
Salt-losing Adrenogenital Syndrome
The recommended dosage for treating salt-losing adrenogenital syndrome is one tablet (0.1 mg) to two tablets (0.2 mg) of FLORINEF daily.
Pediatric and Adolescent: One half tablet (0.05 mg) to one tablet (0.1 mg) daily.
CONTRAINDICATIONS
Corticosteroids are contraindicated in patients with systemic fungal infections and in those with suspected or known hypersensitivity to fludrocortisone or any of the inactive ingredients.